Ryplazim - Priority Review Status
I think it was Gunnerhea who posted that the FDA process would need to be reinitiated. According to Liminal, the previously granted designations will remain. Someone has their facts messed up!
The FDA has indicated that the submission of the amended BLA for Ryplazim® will not impact the previously granted designations, including the Priority Review Status, the Orphan Drug Designation and the Rare Pediatric Disease Designation for Ryplazim® for the treatment of PLDG.